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Abbreviations 
 
ABPM  - ambulatory blood pressure monitoring 
ACE   - angiotensin converting enzyme  
ACEi  - angiotensin converting enzyme inhibitor 
AGE  - advanced glycation end products 
BMI  - body mass index 
CCB   - calcium chanel blocker 
CML  - Nε-carboxymethyl-lysine 
CRP  - C-reactive protein 
cTI  - computerised tubulointerstitial index 
TI  - tubulointerstitial index 
GI  - glomerular index 
VI  - vascular index  
GN  - glomerulonephritis 
IgAN  - IgA nephropathy 
NS   - not significant 
OGTT - oral glucose tolerance test 
qGSI  - qualitative glomerulosclerotic index  
SD   - standard deviation 
TBARS - thiobarbituric acid reactive substances 
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1. INTRODUCTION 
 
IgA nephropathy – also known as Berger’s disease in the literature – is the most common 
form of primary glomerulonephritides.  It occurs in individuals of all ages, but is most common in 
young adults. Diagnosis requires immunofluorescent examination of kidney tissue. Although the 
progression is slow and the disease was thought to have a benign course, on the basis of long term 
follow up 30-40% of patients needs dialysis 20 years after the diagnosis. The investigation and 
recognition of possible factors contributing to the progression of the diasease are of great 
importance.  Because of the relatively slow progression of the disease, patients are followed up for 
many years. During the kontroll examinations (2-4 times a year) great amont of information is 
piled up about the course of the disease. Data needed for controll, treatment and follow up of the 
patients are available only through the study of the patient’s file and other medical documentation. 
It is an extraordinarily difficult, time consuming method with the possibility of errors. The need for 
storing, analysing this significantly great amount of data raised the idea of creating a database, 
which – beyond the storing of the data - can help to recall the stored information according to 
specific criteria, to summarise and export the data for different statistical and matematical 
softwares for more comlex analysis.  Softwares used until recently were not able to completely 
fulfill this need. Our aim was to create a database system using all available medical files of IgAN 
patients, which can considerably speed up safley and this work. Until the end of 2007, medical 
documentation of 320 IgAN patients was processed this way. The database is updated regularly.    
 
Structure of the database 
Each patient in the database has a so-called „static” and a „variing” table consisting of 
different parts with continuously growing amount of the following data:   
 
„Static” table: Personal data, onset of the first symptoms, the diagnosis of IgAN (time of renal 
bipsy), anamnesis, diagnosis of the patient with onset of the diseases, risk factors, family history.  
 
„Variing” table (each time the patient is admitted to the clinic):  Changes in the patient’s 
anamnesis, vital signs, laboratory tests (blood and serum), renal funtion, urine analysis,  diagnostic 
interventions, data about administered drugs and diet.    
 
The database enables the investigation of connenctions between these data with the help of  
biostatistical methods. This is made easier by the fact, that the database is compatible with the 
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most widespread statistical and presentation creating programms, can be updated almost without 
any limitation, even with new types of data if required. The data stored can be called back 
according to special conditions, groupped, or exported for statistical analysis, creating 
presentations etc.   
The complex examination of potential factors playing a role in the progression of the 
disease is possible with analysing the data obtained during the long term observation of IgAN 
patients.  The importance of the examinations shows the fact, that the cause and the exact 
pathomechanism of the disease is not yet known. It is especially important in the light of the fact, 
that the disease’s prevalence is high and 30-40% of the patients need dialysis after 20-25 years 
follow up.  
 
2. HYPOTHESIS AND AIMS 
2.1. Epidemiological data of IgAN patients cared at our clinic.   
Our work is the first national survey on epidemiology and characteristics of IgAN based on 
the database consisting of great amount of data. The following epidemiological questions were 
addressed with the help of the IgAN database:  
 
• the incidence and prevalence of the disease in county Baranya 
• the frequency of the diasease in renal biopsies  
• the age of the patients at the time of renal biopsy 
• the frequency and characteristics of clinical symptoms at onset of the disease 
 
2.2. Investigations of factors influencing the progression of the disease 
2.2.1. Recurrent urinary tract infections.  
Because of the decreased protection of mucous membranes it can be supposed, that the 
prevalence of chronic urinary tract infections with or without symptoms or  that of the significant 
bacteriurias  is increased in IgAN. The urinary tract infections may contribute to the progression of 
IgAN due to the damage of the tubulointerstitium. The following questions were addressed:  
 
 
• the frequency of significant bacteriurias and urinary tract infections among IgAN patients  
• what are the pathogens 
• to what degree are urinary tract infections presented with symptoms? 
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• is the progression of the disease influenced by urinary tract infections? 
• may the unfavourable effect of urinary tract infections on the progression be fended off by 
antibiotic treatment  
 
2.2.2. Tonsillectomy 
The frequent upper respiratory tract infections of IgAN patients often paralell with macroscopic 
haematuria and the frequency of chronic tonsillitides observed even among our patients raised up 
the potential role of tonsills in the pathogenesis of the disease. On the basis of these observations 
tonsillectomy may exert favourable effect on the pathogenesis of the disease by eliminating the 
antibodies.  We looked for aswers for how the  
• urine (proteinuria and haematuria) 
• renal function (creatinin clearance) 
• progression 
• has changed after tonsillectomy.  
 
2.2.3 The 24-hour blood pressure monitoring and the progression of IgAN. 
The early diagnosis and effective treatment of high blood pressure is of special importance in 
chronic glomerulonephritides, even in IgAN, because the connection between the progression of 
renal diseases and hypertension is well known. Numerous investigators found, that renal survival 
of IgAN patients with hypertension is worse compared to patients without hypertension.  
Ambulatory blood pressure monitoring provides a better picture about the daily blood pressure 
compared to casual measurements, even the „white coat effect” and the decrease of diurnal rythm 
is recogniseable. Analysing the data obtained by ambulatory blood pressure monitoring of IgAN 
patients, we were looking answers for the following questions:  
 
• Are there any differences between the mean blood pressure values obtained by ambulatory 
blood pressure monitoring and casual measurements? 
• Diurnal rythm in IgAN patients 
• Prevalance of white coat effect in IgAN 
• Effectiveness of antihypertensive therapy.  
• Is there any connection between results obtained by ambulatory blood pressure monitoring 
(effect of white coat hypertension, presence or absence of diurnal rythm) and the progression 
of IgAN.  
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2.2.4 Antihypertensive drugs with different pathomechanism and the progression of IgAN.  
 
The secunder hypertension developed paralell with the destruction of active renal parenchyma, the 
increased intraglomerular pressure and hyperfiltration causes further damage to the already active 
nephrons.   Thus, normalising blood pressure is of special importance among factors slowing the 
progression of IgAN. Angiotensine converting enzyme inhibitors (ACEi) and the non-
dihydropyridine type calcium channel antagonists (CCB) are very advantageous from this point of 
view, because it’s renoprotective effect is more expressed compared to other types of 
antihypertensive drugs with the same blood pressure lowering ability.  
Long acting drugs (administered 1-2 times a day) have numerous advantages compared to the 
short acting drugs (administered 3-4 times a day): better patient’s compliance, more uniform drug 
effect, resulting in decreased target organ damage. We wanted to investigate the following:  
• effect of short and long acting ACE inhibitors and CCBs compared to each other at the same 
patient 
• comparison of the renoprotective effect of short-, and long acting antihypertensive drugs  
 
2.2.5 Connection of oxidative stress and non-enzymatic glycation in IgAN.  
During non-enzymatic glycation advenced glycation endproducts are formed in human body.  
They play an important role in the progression of renal diseases. AGEs (so the Nε-carboxymethyl-
lisine, CML) are produced because of oxidative stress also, but their serum level may increase due 
to decreased elimination (decreased renal function). Oxidative stress presented during the 
oxidation of LDL is of special importance in the pathogenesis of vascular diseases. But relatively 
few data is available about serum AGE levels and oxidative stress in IgAN until now.  We were 
looking for answers for the following questions:  
 
• Level of non-enzymatic glycation in IgAN (through measuring the circulating serum level of 
fluorescent AGEs and CML)  
• Oxidative stress in IgAN (measuring TBARS) 
• The oxidative resistance and oxidative modification of LDL (change of its TBARS és α-
tocopherol etc. content) 
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2.2.6 Histomorphological and histomorphometrical examinations and progression of IgAN.  
The histological findings using light microscopy in IgAN are not uniform: it may vary from 
minimal lesions to focal or diffuse proliferative glomerulonephritides even with crescents. 
Connection between histological findings, renal function and progression of the disease was 
investigated by lot of investigatiors. The following questions were addressed:   
• is there any connection between the different hisomorphological classifications of IgAN and 
renal function at the time of renal biopsy.  
• what is the connection between histological findings and the change of renal function.  
 
2.2.7 Metabolic syndrome and the progression of IgAN  
 Parts of the metabolic syndrome are cardiovascular risk factors on their own, but their common 
effect is much more harmful.  Aim of our study was to investigate:  
• the prevalence of the metabolic syndrome and it’s components in IgAN.  
• connection between the components of metabolic syndrome and progression of IgAN.  
 
 
3. METHODS AND RESULTS 
 
3.1. Epidemiological data of IgAN patients cared at our clinic.   
IgAN was diagnosed in 17.5% of renal biopsies at our clinic between 2002 and 2005 
(32.4% among primary glomerulonephritides). It meant 61 newly diagnosed IgAN patients.  
Mean follow up was 12 ± 7 years. Until the end of 2006, our database consisted of 287 
patient’s data (209 male,  78 female), female/male ratio 1/2.68.   
The distribution of IgAN patients at renal biopsy according to their age was:  0-20 years, 
n=37 (12,89%), 21-30 years, n=76 (26,48%), 31-40 years, n=78 (27,17%), 41-50 years, n=57 
(19,86%), 50-60 years, n=30 (10,45%), 61-70 years, n=6 (2,10%), 71-80 years, n=3 (1,05%).  
Follow up time: 0-5 years, n=134 (46,69%), 6-10 years, n=54 (18,81%), 11-15 years, n=29 
(10,10%), 16-20 years, n=32 (11,15%), >20 years fölött, n=38 (13,24%). Proteinuria: <0,5 g/day, 
n=61 (29,47%), 0,5-3 g/day, n=124 (59,91%), >3 g/day, n=22 (10,62%). Haematuria at the 
diagnosis: haematuria, n=183 (63,76%), no haematuria, n=104 (36,24%). Hypertension at the 
diagnosis: known hypertension, n=99 (34,49%), hypertension, not yet known, n=20 (6,97%), no 
hypertension, n=168 (58,54%).  
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3.2. Investigations of factors influencing the progression of the disease 
3.2.1. Recurrent urinary tract infections.  
Microbiological tests of the urine were made at each control examination (every 3-6 months) 
independently of the patient’s symptoms. The controll group consisted of 19 IgAN patients 
without urinary tract infection. During the follow up the following parameters were recorded every 
6-12 months: serum creatinin, serum carbamid nitrogen, creatinine clearance, blood sedimentation 
rate, serum potassium, blood pressure, presence of haematuria, proteinuria. Data were analysed 
retrospective.  
76 patients file was analysed, bacteriurias were found in 19 patients (1-5 times). Frequency of 
bacteriurias was 0,21/pts/year. Total number of bacteriurias were 37 (29 presented without 
symptoms). The recurrent infections were caused by the same bacteria in 10 cases. Creatinine 
clearance decreased in both groups during the 8,42 years follow up (UTI group: from 102,82 ± 
37.6 ml/min to 88,07 ± 30.47 ml/min, controll group: from 98,69 ± 37,74 ml/min to 72,49 ± 34,21 
ml/min, not significant).  
 
3.2.2. Tonsillectomy 
The history of 50 IgAN patients with tonsillectomy was investigated. The controll group 
consisted of 60, age, sex, renal function, follow up time matched IgAN patients with chronic 
tonsillitis. The mean survival time from renal biopsy to creatinin clearance<80 ml/min/1,73m2 was 
143,8±13,9 months in patients with tonsillectomy, and 117,9±12,4 months without tonsillectomy. 
The mean survival time to ESRD was 229,9±8,4 and 208,2±9,2 months in the two groups. 
Differences were not significant.   
Using Cox-regression analysis, tonsillectomy and decreased proteinuria had favourable 
influence on time to creatinin clearance<80 ml/min/1,73m2, but tonsillectomy had no favourable, 
significant effect on time to ESRD.  
 
3.2.3 The 24-hour blood pressure monitoring and the progression of IgAN. 
126, biopsy proven IgAN patients were involved in the study. Ambulatory blood pressure 
monitors (Meditech, type 02-03) were used for 24 hours (daytime: every 15 minutes, nighttime: 
every 20 minutes). Casual measurements were made on three times, in sitting position after 5 
minutes rest. 55 patients were normotensive (36 male/19 female, mean age 37.7 ± 10 years), 71 
patients hypertensive (57 male/14 female, mean age 46.4 ± 12 years).  
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 Comparison of the blood pressure values measured by ABPM and casual measurements. 
The mean blood pressure levels in IgAN patients were higher (135.7±14.0 / 87.8±8.8 mmHg) 
compared to 24-hour (126.3±10.2 / 82.3±8.8 mmHg), daytime (127.2±10.2 / 83.3±9.5 mmHg) and 
nighttime (123.6±14.8 / 79.1±11.5 mmHg, p<0.005) blood pressure values obtained by ABPM.  
The diurnal rythm of blood pressure. The 82 % of the normotensive IgAN patients were 
„dipper” (41/55) and 93 % (66/71) of  hypertensive IgAN patients were „non-dipper”.  
White coat hpertension. Ten normotensive patients was thought to have hypertension on the 
basis of casual measurement (mean blood pressure 149±7/96±8 mmHg), but significantly lower 
blood pressure levels were found using ABPM (mean: 127±6/83±5 mmHg, P<0.05). White coat 
hypertension was observed at 14 treated hypertensive patients (mean blood pressure: 152±8/98±6 
mmHg, ABPM: 130±4/85±8 mmHg, P<0.05). 
Effectiveness of the antihypetensive treatment. No difference was found between the mean 
daytime blood pressure of normotensive and treated hypertensive IgAN patients measured by 
ABPM. Normotensive patients had signifficantly lower nightime blood pressure compared to 
treated hypertensive IgAN patients.  
 
3.2.4 Antihypertensive drugs with different duration time and pathomechanism and the 
progression of IgAN.  
Data of 22, hypertensive, biopsy proven IgAN patients were analysed (male/female: 18/4, 
mean age at onset:  32.45 ± 9.53 years, mean follow up time 7.25 ± 2.36 years). After treatment 
with short acting ACE inhibitors (captopril, n=20) and/or dihydropyridine type CCBs (nifedipine, 
n=13) for at least 3 years, long acting ACE inhibitors (enalapril, n=18, cilazapril, n=4) and/or 
CCBs (diltiazem hydrochlorid, n= 16) were used. Short acting drugs were administered three 
times, long acting ones two times a day. At each controll examination the values of seum creatinin, 
creatinine clearance and the level of proteinuria was recorded. Just before the shift to the long 
acting drugs and three years after that shift ABPM examinations were made. Proteinuria and 
creatinine clearance was measured at the same time.   
To estimate the progression of IgAN patients we calculated the slope of 1/creatinine values 
during the years of both short and long acting administration of drugs. After the shift to the 
administration of long acting drugs the slope of the 1/creatinine values and the level of proteinuria 
significantly decreased. Creatinine clearance values did not change significantly.  
 
 10
 
3.2.5 Connection of oxidative stress and non-enzymatic glycation in IgAN.  
88 IgAN patients were involved in the study. They were devided into two groups according 
to their renal function. Patients with normal renal function (creatinine clearance ≥ 80 ml/min) 
made up the first group (creatinin clearance 106 ± 22 ml/min, n=54) and patients with decreased 
renal function (creatinin clearance 51 ± 19 ml/min, n= 34) made up the second one. Healthy 
volunteers with normal renal function made up the control group (creatinin clearance 102 ± 24 
ml/min, 18 female, 44 male, mean age 32 ± 11 év). OGTT was made at the same time.  
Serum AGE level was measured by determination of AGE-FL and CML levels. The level 
of AGE-FL was measured using fluorescent spectrofotometer (Hitachi F-4500, with excitation 
wave lenght of 370 nm, and emission wave lenght of 440 nm). CML was measured by competitive 
ELISA method. The mean values of three measurements on each sample were used at our 
calculations.  
To determine the level of the oxidative stress, the level of TBARS was measured using 
fluorescent spectrofotometer described by Jentzsch (with excitation wave lenght of 532 nm, and 
emission wave lenght of 553 nm).  
Oxidative stress/glycation parameters and renal function. Significantly elevated TBARS 
levels were found in both the plasma and in the LDL particles of patients with normal and elevated 
renal function (p < 0.001), parelell with the decreased oxidative resistance of LDL (p < 0.04). 
AGE-FL and CML levels did not differed significantly in IgAN patients with normal renal 
function compared to controll group. But these levels were significantly elevated in patients with 
decreased renal function.  
Oxidative stress/glycation parameters and glucose metabolism. The AGE levels and 
parameters of oxidative stress were influenced only to a minor degree by the initial disorder of 
glucose metabolism. The oxidative resistance was significantly decreased in patients with both 
normal and disturbed glucose metabolism compared to controll group after adjustment for age and 
renal function.  
Among IgAN patients with disturbed glucose metabolism AGE-FL and CML levels were 
elevated only in patients with decreased renal funcion compared to controlls. But TBARS levels 
were significantly elevated in IgAN patients with both normal and decreased renal function 
compared to controll group. In the same way, among IgAN patients with normal glucose 
metabolism (n=67), the AGE-FL and CML levels were higher only in patients with decreased renal 
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fnction, when compared to contolls.  In IgAN patients with normal glucose metabolism TBARS 
levels were elevated in patients with both normal and decreased renal function.  
 
 Connection between AGE-s and renal function. In all of the IgAN patients (n=88) significant 
correlation was found between creatinine clearance and AGE-FL, CML levels.  
Correlation between oxidative resistance of LDL and it’s α-tocopherol content. IgAN patients 
were devided into two groups: patients with α-tocopherol content below (< 8.34 mol/mol ApoB, 
mean: 7.32 ± 1.02 mol/mol ApoB, n = 49) and above (> 8.34 mol/mol ApoB, mean 9.54 ± 1.39 
mol/mol ApoB, n = 39) the mean value of α-tocopherol level. The oxidative resistance was 
significantly lower and the TBARS content of LDL was significantly higher in IgAN patients with 
low α-tocopherol content, compared to patients with high α-tocopherol content and controlls. The 
TBARS content of LDL was significantly higher in patients with high α-tocopherol compared to 
controlls.  
 
3.2.6. Connection between histomorphological and histomorphometrical findings and progression 
of IgAN. 
 
Only biopsies with at least 6 glomeruli were examined. This criteria was fulfilled in 128 
cases among biopsies executed between 1975 and 2000 at our clinic.  WHO classification was 
applied for histomorphological examinations. Histomorphometrical examinations were made 
according to Risdon (tubulointerstitial index), Kusumoto (glomerular index) and Bader (vascular 
index). The qGSI index was determined by the modification of the method described by Vleming.  
During the computerised analysis of the interstitium (cTI) photos of the slides stained by 
Masson-trichrom were recorded using a digital kamera (Ikegami, 10 field of view each case, 400x 
magnification). No glomeruli, arteries, dilated tubuli were recorded. At each picture blue colour 
showing the interstitium was marked using the Adobe Photo Shop computer programm, and it’s 
area calculated by the Scion Image program. To obtain the cTI, the calculated values were 
averaged (10-10 photo at each case). The above measurements were made by a pathologist without 
any information obout the patients clinical or laboratory data.     
Patients were grouped by the histological indices (WHO: 4 groups, TI: 4 groups, GI: 5 
groups, VI: 3 groups, qGSI-A és qGSI-B: 4-4 groups). Time from the diagnosis of the disease to 
the endpoints (serum creatinine>200 umol/l, serum creatinine>500 umol/l, creatinin clearance <80 
ml/min) was calculated by Kaplan-Meier analysis and the difference was analysed by log-rank test 
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between the groups. Factors influencing the time until the endpoints were analysed by Cox-
regression analysis.  
Data of patients grouped on the basis of the WHO classification and time to the different 
end points are shown in Table 1.  
 
 
 
WHO 1 WHO 2 WHO 3 WHO 4-5 
 
No of patients (n= ) 14 31 42 39 
 
Age (year) 36.79 ± 9.10 31.87 ± 12.82 30.07 ± 8.86 37.77 ± 12.73 
Serum creatinine 
(umol/l) 95.86 ± 16.10 94.16 ± 23.38 97.33 ± 21.00 123.61 ± 93.70 
Creatinine clearance 
(ml/min/1.73 m2) 93.43 ± 16.30 92.13 ± 23.25 95.68 ± 19.65 75.45 ± 30.40 
Time until creatinine 
clearance < 80 ml/min/1.73 
m2 (months) 
158 ± 135 146 ± 139 125 ± 116 71 ± 112 a 
Time until serum 
creatinine > 200 umol/l 
(months) 
- + 234 ± 128 206 ± 130 b 231 ± 175 b 
Time until serum 
creatinine > 500 umol/l 
(months) 
- + 256 ± 95 228 ± 123 256 ± 180 
a
 vs. WHO 1-3, p < 0,05, 
b
 vs. WHO 1, p < 0,05, 
+
 all of the patients are censored 
Table 1.  Data of patients grouped on the basis of the WHO classification at renal biopsy and time 
to different end points.  
 
Paralell with the worsening of the tubulointerstitial changes the time to different endpoints 
were gradualy decreased. The same tendency was found in case of the vascular index. In the 
different GI groups only the group with modest histological changes showed significantly better 
outcome compared to the other GI groups.  
Completely scarred glomeruli was found in 43 out of the 98 cases. Examinations were 
made involving   (qGS.I.-B) and excluding (qGS.I.-A) these glomeruli. Paralell with the worsening 
of qGS.I., the time until endpoints decreased. Significantly poorer outcome at each endpoint was 
found only in patient group with the worst qGS.I. (both qGS.I.-B and qGS.I.-A) compaired to other 
qGS.I. groups.  
Time from renal biopsy to serum creatinine >265 umol/l („point of no return”) was 
significantly infuenced by T.I. (p<0.001), V.I. (p=0.03), qGS.I.-A (p<0.001), qGS.I.-B (p<0.03) 
and the cTI. (p=0.001), and time to creatinine clearance <80 ml/min was influenced by V.I. 
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(p=0.005), qGS.I.-A (p<0.02), and qGS.I.-B (p<0.05). Only tubulointerstitial index exerted 
significant influence on time to ESRD (p<0.001).  
 
4.2.7 Metabolic syndrome and the progression of IgAN.  
The folowing parameters of 163 IgAN patients were determined: blood pressure, serum 
triglicerid, HDL, cholesterol, LDL, uric acid, fasting glucose, serum creatinine, creatinine 
clearance. The number of metabolic syndrome components were calculated at each patients at 
renal biopsy.  
 
• Impaired glucose metabolism (impaired fasting glucose, impaired glucose tolerance, 
diabetes mellitus).  
• Hypertension (treated or repeated casual blood pressure ≥ 140/90 mmHg based on WHO 
criteria).  
• Dyslipidaemia (serum triglycerid ≥1.7 mmol/l, total cholesterol > 5.2 mmol/l, LDL > 3.4 
mmol/l, or HDL < 1.0 mmol/l). 
• Obesity (body mass index ≥ 27 kg/m2). 
 
Fifty out of the 163 patients (30.7%) had already metabolic syndrome. Its importance is 
underlined by the fact, that their mean age at diagnosis was only 33.4±10.2 years. At the diagnosis 
og IgAN, 68.1% of patients had at least 2 metabolic syndrome components. In patients with 2-4 
metabolic syndrome components the time to both examined endpoints (creatinine clearance<80 
ml/min and serum creatinine>500 umol/l) was significantly shorter compaired to patients with 0-1 
components.  
 
4. DISCUSSION  
4.1  Epidemiological data of IgAN patients cared at our clinic.   
IgAN usually starts at younger ages. No national data about the incidence of IgAN based 
on renal biopsies was avaiable so far. From 1977, 314 IgAN patients were diagnosed at our clinic. 
66 percent of these patients were younger, than 40 years old, and only 3.13% were older, than 60 
years at the time of diagnosis.  Because of the relatively slow progression of the disease, the long 
term follow up of patients has great importance. More, than half of our patients (53.3%) has been 
followed up for more than 5 years, and 24.4 % of patients has been followed up for more than 15 
years.  
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The microscopic and macroscopic haematuria followed 1-2 days after infections is 
characteristic for the disease. Similar to other publications, microscopic or macroscopic haematuria 
was found at 63.76% of patients examined first time at our clinic. Presence of heavy proteinuria is 
not typical, only 7.66% of cases presented with expressed (>3g/day) proteinuria at diagnosis. 
Considerably, almost half of our patients (41.46 %) has had hypertension at onset.  
 
4.2. Investigations of factors influencing the progression of the disease 
4.2.1. Recurrent urinary tract infections.  
Decreased protection of mucous membranes observed in IgAN, the more frequent urinary 
tract infection without symptoms may exert an unfavourable influence on the progression of the 
disease due to damage of the interstitium.  Urinary tract infection was observed in 25 % of patients 
followed up for at least 3 years, caused mainly by Gramm negativ bacteria. The progression of 
IgAN in these patients was not faster compared to the age, sex, follow up time matched controll 
group. The early treatment with antibiotics (for 7-10 days or continuously for months if they offen 
recur) may have fended off the unfavourable effect of chronic urinary tract infections causing 
tubulointerstitial damage. Although not signifficant, the decrease in creatinine clearance during 
follow up was suprisingly smaller in urinary tract infections group, arising the old assumption, that 
antibodies causing IgAN originate from infections. Treatment with antibiotics may decrease the 
amount of antigens, and thus the immuncomplexes.   
 
4.2.2. Tonsillectomy 
 
On the basis of our data, tonsillectomy had no statistically relevant favourable effect on the 
prgression of the disease. The minor difference in survival time until the endpoint of serum 
creatinin<80 ml/min/1.73 m2 practically disappeared if time to ESRD was investigated. Similarly, 
tonsillectomy had favourable effect in Cox regression analysis, only if endpoint was the time to 
serum creatinin<80 ml/min/1.73 m2. We can assume, that tonsillectomy has no significant effect 
on the outcome of IgAN, despite the short term (1-2 years) favourable effect on 
haematuria/proteinuria.  
 
4.2.3 The 24-hour blood pressure monitoring and the progression of IgAN. 
On the basis of our data, the dipper/non-dipper ratio in normotensive IgAN patients and 
healthy controlls are similar, but 93 % of hypertensive IgAN patients are non-dipper.  
The unfavourable cardiovascular effect of non-dipper blood pressure values is well known. 
The „white coat hypertension” was described even in the mild forms of essential hypertension. 
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This phenomenon was observed even in 18% of our normotensive patients. This is similar to the  
frequency of „white coat hypertension” observed in essential hypertension. We found „white coat 
hypertension” in 20% of our treated hypertensive patients. Neglecting this fact may lead to 
administration of antihypertensive drugs to otherway normotensive patients, or the dose in 
hypertensive patients may be overestimated. Hypotension may lead to decrease in GFR due to the 
decreased intraglomerular filtration pressure. Even the psychological effect of the awareness of 
hypertension and the cost of unnecessary administered drugs can not be neglected.  
The daytime blood pressure in normotensive and treated hypertensive IgAN patients did 
not differ significantly, but the night time blood pressure decrease was absent in treated 
hypertensive patients, partially explaining the faster deterioration of renal function in treated 
hypertensive patients. The early, effective antiyhpertensive treatment, the re-establishment of 
diurnal rythm of the blood pressure may deleay the developement of ESRD.  
 
4.2.4 Antihypertensive drugs with different duration and pathomechanism and the progression of 
IgAN.  
The effect of short-, and long acting drugs on the disease’ progression was not 
investigated in the same IgAN patients so far. Long acting antihypertensive drugs are more 
favourable compared to short acting ones, due to better compliance of patients and their more 
uniform effect.  The change of the slope of 1/creatinine regression lines after administration of 
long acting antihypertensive drugs supports these assumptions.  
   On the basis of our data, during the administration of long acting antihypertensive drugs 
blood pressure values were lower, independently of the part of the day, but only 24 hour diastolic 
blood pressure, the 24 hour hypertensive time index, and 24 hour diastolic hyperbaric impact 
showed signifficant difference. The effect of long acting drugs on the decrease of night time blood 
pressure is more expressed, the mean value of the diurnal index was elevated in our study.   
During the administration of long acting antihypertensive drugs the proteinuria and the progression 
of IgAN significantly decreased.  
 
4.2.5 Connection of oxidative stress and non-enzymatic glycation in IgAN.  
Oxidative stress is caused by free radicals formed during oxidation-reduction reactions. 
Under normal conditions specific enzimatic and non-enzymatic reactions eliminates the free 
radicals. The imbalance between the production and elimination of free radicals may lead to 
damage of different organs. Using numerous markers of oxidative stress many publications 
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proved, that under uraemic conditions oxidative stress is increased. According to some data, 
increased oxidative stress may be observed even before the developement of ESRD.  
We found significantly elevated amount of TBARS in serum and in LDL, and decreased 
oxidative resistance of LDL  in IgAN patients compared to healthy controlls. This increased level 
of oxidative stress was not influenced neither by the renal function nor the glucose metablism of 
the patients.  
The AGE levels were not investigated in IgAN patients so far. The AGE-FL and CML levels were 
not higher in IgAN patients with normal renal function, but these levels were significantly elevated 
in IgAN patients compared to patients with normal renal functions, or to contolls.   
 These observation supports the idea, that decreased renal function is responsible for the elevated 
AGE-FL and TBARS levels in IgAN. The LDL of IgAN patients with higher LDL α-tocopherol 
content had increased oxidative resistance independently of renal function.  
Increased oxidative stress seems not to be specific for IgAN, because the same observations 
were made in the early stages of other glomerulopathies. On the basis of our present and previous 
examinations the elevated AGE levels in decreased renal function is independent of the underlying 
kidney disease.  
 
5.2.6. Connection between histomorphological and histomorphometrical findings and progression 
of IgAN. 
 
In patients grouped by the WHO classification the WHO I-II-III groups showed a tendency 
for deteriorating renal function, but without significance. No difference was observed between 
WHO group IV-V. On the basis of our data, from prognostic point of view, WHO I-V. 
classification may be replaced by two groups: patients with good prognosis (WHO I-III), and with 
poorer one (WHO IV-V).  
On our opinion the progressive renal insuffitiency is the consequence of 
glomerulosclerosis, tubulointerstitial fibrosis and vascular sclerosis. On the basis of  our results in 
early stages of renal disease glomerular and tubulointerstitial changes plays an equal role, but in 
the developement of ESRD the tubulointerstitium plays a definite role. Taking scared glomeruli 
into account did not influenced the assessment of the progression.   
 
5.2.7 Metabolic syndrome and the progression of IgAN.  
The syndrome is important partly because of their frequency, and partly the increased 
oxidative stress, the associated atherosclerosis, and target organ damages as a consequence. The 
components of metabolic syndrome are itself independent cardiovascular risk factors.   
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The early diagnosis of the syndrome or their components is the basis of it’s treatment. 
Metabolic syndrome resembles an iceberg, where the peaks (the components of the metabolic 
syndrome) are targets of the therapeutic interventions.  
The increased incidence of metabolic syndrome, similarly to the hungarian population, was 
observed also in our IgAN patients. It is worth mentioning, that in 30 % of IgAN patients 
metabolic syndrome was observed already at the time of diagnosis.    
Considering the low age of patients at diagnosis and the increasing prevalence of metabolic 
syndrome paralell with time, it may considerably contribute to the deterioration of renal function, 
to the increased cardiovascular morbidity and mortality.  
On the basis of our observations, the unfavourable effect of the metabolic syndrome on the 
progression of IgAN was proved, resulting in decreased renal survival time to both mild renal 
damage and ESRD.  
This effect was already obsereved not only in patints with metabolic syndrome, but in 
patient having at least two metabolic syndrome components.  
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5. LIST OF THE Ph.D. THESES:  
 1. Our work is the first national survey on epidemiology and characteristics of IgAN based on the 
database consisting of great amount of data.  
2. The early diagnosis and treatment of recurrent urinary tract infections in IgAN may account for 
the fact, that these patient’s prognosis don’t differs from the prognosis of patients without urinary 
tract infections.    
3. Tonsillectomy made because of frequent upper respiratory tract infections has no influence on 
the long term progression of the disease.  
4. The early diagnosis and treatment of hypertension is of special importance in the decrease of the 
progression. 
 a) With our ABPM examinations we described at the first time the mean characteristics of IgAN 
patient’s hypertension. Among these factors the absence of the diurnal rythm (in both 
normotensive and hypertensive patients), and the presence of „white coat hypertension” are most 
important.  
 b) We proved at the first time in IgAN, that the shift from short-, to long acting antihypertensive 
drugs can decrease the progression of the disease paralell with the more uniform antiyhpertensive 
effect.  
 5. We proved for the first time (together with our previous observations), that oxidative stress is 
increased already in patients with normal renal function, but the serum level of AGEs tends to 
increase only paralell with the decrease of renal function. The oxidative resistance of LDL is 
increased in patients with higher LDL α-tocopherol content, independently of renal function.  
6. Using different morphometrical and morphological methods, glomerular, tubulointerstitial, 
vascular changes were analysed. Even our new observations have proved the role of the 
tubulointerstitial damages in the IgAN’s long term prognosis.  
 7. 30% of patients has metabolic syndrome already at the time of diagnosis, other patients develop 
the syndrome during the course of the disease. Patients with metabolic syndrome has clearly 
poorer outcome.  
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